Cipla has a total of 3490 patents globally, out of which 1470 have been granted. Of these 3490 patents, more than 61% patents are active. India is where Cipla has filed the maximum number of patents, followed by United States Of America and Europe. Parallelly, India seems to be the main focused R&D center and is also the origin country of Cipla.
Cipla was founded in 1935 by Khwaja Abdul Hamied. Cipla manufactures and sells pharmaceutical and personal care products. The Company offers active pharmaceutical ingredients, and formulations in therapeutic areas, such as allergy, analgesic, anti-malarial, anti-infectives, cardiology, dermatology and cosmeceuticals, diabetology, gastroenterology, steroids, iron chelators, nutritional products. As of May 2022, Cipla has a market cap of $10.35 Billion.
Do read about some of the most popular patents of Cipla which have been covered by us in this article and also you can find Cipla patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Cipla patent portfolio.
How many patents does the CEO of Cipla have?
The CEO, Umang Vohra has 0 patents.
How many patents does Cipla have?
Cipla has a total of 3490 patents globally. These patents belong to 1090 unique patent families. Out of 3490 patents, 1328 patents are active.
How Many Patents did Cipla File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Cipla Applications Filed | Cipla Patents Granted |
| 2010 | 185 | 80 |
| 2011 | 176 | 102 |
| 2012 | 96 | 123 |
| 2013 | 176 | 98 |
| 2014 | 122 | 82 |
| 2015 | 109 | 98 |
| 2016 | 83 | 53 |
| 2017 | 103 | 30 |
| 2018 | 99 | 44 |
| 2019 | 62 | 42 |
| 2020 | 34 | 23 |
| 2021 | 22 | 33 |
| 2022 | 4 | 12 |
Which Cipla Drug Patents are Expiring in the Next 10 Years?
The patent no. US9688711B2 which is expiring in Nov, 2028, describing a potent antibacterial drug, derived from a complex hydrophobic molecule with a structure similar to proteins rather than simple DNA motifs, is effective for treating bacterial infections.
Given below is the list of few drugs patented by Cipla accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.
| Drug Name | Patent Number | Patent Title | Patent Expiration |
| Zemdri | US9688711B2 | Antibacterial Aminoglycoside Analogs | Nov, 2028 |
Interested in knowing about Cipla’s Drug Patents Expiring in the next 10 years?
How many Cipla patents are Alive/Dead?
Worldwide Patents
How Many Patents did Cipla File in Different Countries?
Countries in which Cipla Filed Patents
| Country | Patents |
| India | 677 |
| United States Of America | 314 |
| Europe | 229 |
| Australia | 204 |
| Canada | 163 |
| Japan | 160 |
| South Africa | 158 |
| Korea (South) | 151 |
| New Zealand | 99 |
| Germany | 91 |
| China | 80 |
| Russia | 76 |
| Brazil | 70 |
| United Kingdom | 66 |
| Mexico | 59 |
| Hong Kong (S.A.R.) | 40 |
| Spain | 35 |
| Austria | 32 |
| Turkey | 31 |
| Israel | 30 |
| Argentina | 25 |
| Indonesia | 22 |
| Singapore | 21 |
| Viet Nam | 21 |
| Portugal | 20 |
| Malaysia | 20 |
| Morocco | 18 |
| Poland | 18 |
| Philippines | 17 |
| Chile | 17 |
| Denmark | 16 |
| Peru | 14 |
| United Arab Emirates | 13 |
| Tunisia | 12 |
| Panama | 11 |
| Uruguay | 10 |
| Taiwan | 10 |
| Cyprus | 9 |
| Dominican Republic | 9 |
| Slovenia | 9 |
| Norway | 8 |
| Ecuador | 8 |
| Iceland | 8 |
| Costa Rica | 7 |
| Hungary | 6 |
| Latvia | 5 |
| Ukraine | 5 |
| Croatia | 4 |
| Kazakhstan | 4 |
| Czech Republic | 4 |
| Colombia | 4 |
| Switzerland | 4 |
| Romania | 4 |
| Greece | 3 |
| Jordan | 3 |
| Lithuania | 3 |
| Laos | 3 |
| Egypt | 3 |
| El Salvador | 2 |
| Honduras | 2 |
| Italy | 2 |
| Botswana | 2 |
| Brunei | 2 |
| Georgia | 2 |
| Serbia | 1 |
| Macao | 1 |
| Bulgaria | 1 |
| Rwanda | 1 |
| Bolivia | 1 |
| Luxembourg | 1 |
| Estonia | 1 |
| Azerbaijan | 1 |
| Slovakia | 1 |
| Paraguay | 1 |
| San Marino | 1 |
| Belarus | 1 |
| Kenya | 1 |
| Kyrgyzstan | 1 |
| Bangladesh | 1 |
Where are Research Centers of Cipla Patents Located?
10 Best Cipla Patents
US20040213744A1 is the most popular patent in the Cipla portfolio. It has received 163 citations so far from companies like Medpharm Limited and Arcion Therapeutics.
Below is the list of 10 most cited patents of Cipla:
| Publication Number | Citation Count |
| US20040213744A1 | 163 |
| US6962691B1 | 129 |
| WO2004019985A1 | 113 |
| WO2007007110A1 | 83 |
| WO2008035109A1 | 79 |
| WO2006024863A1 | 75 |
| US7022698B2 | 67 |
| WO2005108386A1 | 57 |
| US6348458B1 | 55 |
| WO2010067072A1 | 55 |
Which Companies are using Cipla Patents to Advance their Research?
If patents or patents from a particular technology area of a company receive a lot of citations, it implies that the technology is being followed and incrementally innovated by the citing companies. It also indicates that citing companies are working on similar and closely related technologies.
The top citing companies in the Cipla patent portfolio are 3M, O-Ray Pharma and Afgin Pharma.
List of the top forward citing Companies –
| Company | Number Of Patents |
| 3M | 2 |
| O-Ray Pharma | 2 |
| Mexichem Fluor Sa De Cv | 2 |
| Afgin Pharma | 2 |
| Ratiopharm | 2 |
| Althera Life Sciences | 2 |
| Leo Pharma A/S | 2 |
| Chiesi Farmaceutici Spa | 2 |
| Neuroderm | 2 |
| Daiichi Sankyo | 2 |
Count of 102 and 103 Type Rejections based on Cipla Patents
Top Cipla Patents used in Rejecting Most Patent Applications
| Patent Number | Count of Rejected Applications |
| US6962691B1 | 7 |
| US20040213744A1 | 7 |
| US7638627B2 | 6 |
| US8168620B2 | 6 |
| US20070219171A1 | 5 |
| US20070286814A1 | 5 |
| US8269003B2 | 4 |
| US8633234B2 | 4 |
| US9968771B2 | 4 |
| US8962601B2 | 3 |
What Percentage of Cipla US Patent Applications were Granted?
Cipla (Excluding its subsidiaries) has filed 274 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 152 have been granted leading to a grant rate of 61.04%.
Below are the key stats of Cipla patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Cipla?
| Law Firm | Total Applications | Success Rate |
| Conley Rose | 137 | 63.78% |
| Meunier Carlin & Curfman | 42 | 73.53% |
| Macmillan Sobanski & Todd | 22 | 13.64% |
| Cooley | 11 | 72.73% |
| Polsinelli | 10 | 50.00% |
| Bass Berry & Sims | 5 | 80.00% |
| Dykema Gossett | 5 | 40.00% |
| Venable | 5 | 100.00% |
| Cantor Colburn | 4 | 0.00% |
| Haynes And Boone | 4 | 25.00% |
EXCLUSIVE INSIGHTS COMING SOON!
What are Cipla key innovation segments?